Tharimmune (NASDAQ: THAR) outlines registered offering pricing in 8-K filing

Rhea-AI Filing Summary

Tharimmune, Inc. filed a current report describing a recent capital markets development. The company announced that it issued a press release on January 20, 2026, detailing the pricing of a registered offering of its securities. The press release is included as an exhibit to the report and is incorporated by reference, indicating that key terms of the offering are set out in that accompanying document.

Insights

Capital markets and SEC disclosure analyst

Tharimmune reports the pricing of a registered offering via press release.

Tharimmune, Inc. used this current report to formally note that it has priced a registered offering and to file the related press release as an exhibit. This type of disclosure keeps the market informed that new securities are being offered under an effective registration, with the specific terms detailed in the attached press release.

The development signals that the company is accessing public capital markets, but the size, structure, and potential dilution or balance sheet impact are contained in the press release itself rather than this summary. Investor interpretation will largely depend on those offering terms and how the additional capital aligns with the company’s strategic and funding needs.

false 0001861657 0001861657 2026-01-20 2026-01-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) January 20, 2026

THARIMMUNE, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-41210		84-2642541
(State or other jurisdiction of incorporation)		(Commission File Number)		(I. R. S. Employer Identification No.)

34 Shrewsbury Avenue, Suite 1C

Red Bank, NJ 07701

(Address of principal executive offices, including zip code)

(732) 889-3111

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, $0.0001 par value		THAR		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On January 20, 2026, Tharimmune, Inc. (the “Company”) issued a press release announcing the pricing of a registered offering. A copy of the press release is attached hereto as Exhibits 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description of Exhibit
99.1		Press Release, dated January 20, 2026
104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.

-2-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: January 20, 2026	Tharimmune, Inc.
	/s/ Mark Wendland
	Mark Wendland
	Chief Executive Officer

-3-

FAQ

What did Tharimmune (THAR) disclose in this 8-K filing?

Tharimmune, Inc. disclosed that it issued a press release on January 20, 2026 announcing the pricing of a registered offering, and filed that press release as an exhibit.

What is the main purpose of Tharimmune’s January 20, 2026 8-K?

The main purpose is to inform investors that Tharimmune has priced a registered offering of its securities and to make the related press release publicly available as an exhibit.

Where can investors find details of Tharimmune’s registered offering pricing?

Detailed terms of the offering are contained in the Tharimmune press release dated January 20, 2026, which is filed as Exhibit 99.1 and incorporated by reference.

Which exhibit in the 8-K contains Tharimmune’s press release?

Exhibit 99.1 contains the Tharimmune, Inc. press release dated January 20, 2026 that announces the pricing of the registered offering.

Does the filing state Tharimmune’s stock exchange and trading symbol?

Yes. The filing notes that Tharimmune’s common stock trades on The Nasdaq Stock Market LLC under the symbol THAR.

Who signed Tharimmune’s January 20, 2026 8-K report?

The report was signed on behalf of Tharimmune, Inc. by Mark Wendland, who is identified as the Chief Executive Officer.